Dominik Selleslag, Dominik

dr. Dominik Selleslag

Hematologie

Behandeling op maat voor acute myeloïde leukemie

Behandeling op maat voor acute myeloïde leukemie

Acute myeloïde leukemie – AML – is de meest voorkomende vorm van acute leukemie bij volwassenen (incidentie: 2 tot 3 per 100.000 personen). De incidentie stijgt met de leeftijd, waardoor AML hoofdzakelijk een aandoening is van de oudere patiënt. De behandeling wordt bepaald door de leeftijdscategorie, de comorbiditeit en het cytogenetisch-moleculair onderzoek.

X-linked sideroblastic anemia and ataxia: A new family with identification of a fourth ABCB7 gene mutation.

Eur J Paediatr Neurol. 2012 Nov;16(6):730-5. doi: 10.1016/j.ejpn.2012.02.003.
06.03.2012

» http://www.ncbi.nlm.nih.gov/sites/

Postuniversitair Centrum KUL campus West-Vlaanderen, Postacademische cyclus geneeskunde. Aanwinsten in de oncologie en haematologie. Dr. Ann Janssens en Dr. Timothy Devos. Nieuwe ontwikkelingen bij CLL, CML en MGUS.

09.02.2010

» http://www.ncbi.nlm.nih.gov/sites/

Belgian Hematological Society 29 en 30.01.10, te Oostende. – Is there an increased incidence of plasmablastic transformation in multiple myeloma after treatment with Imids and bortezomib?

Oostende, Belgium
29.01.2010

» http://www.ncbi.nlm.nih.gov/sites/

Posterabstract Belgian Hematological Society 29 en 30.01.10, te Oostende. Histiocytic sarcoma after acute precursor B lymphoblastic lymphoma: Case report.

Oostende, Belgium
29.01.2010

» http://www.ncbi.nlm.nih.gov/sites/

Posterabstract Belgian Hematological Society 29 en 30.01.10, te Oostende. Mixed phenotype acute leukaemia with MLL/AF4 rearrangement: A case report with sudden lineage switch.

Oostende, Belgium
29.01.2010

» http://www.ncbi.nlm.nih.gov/sites/

American society of haematology, New Orleans, USA. Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups.

05.12.2009

» http://www.ncbi.nlm.nih.gov/sites/

American Society of Haematology, New Orleans, USA. RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004) .

05.12.2009

» http://www.ncbi.nlm.nih.gov/sites/

American Society of Haematology, New Orleans, USA. Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

05.12.2009

» http://www.ncbi.nlm.nih.gov/sites/

Postuniversitair Centrum KUL campus West-Vlaanderen. Recente vooruitgang in Alzheimeronderzoek suggereert mogelijkheden tot therapie. Prof Dr. Bart De Strooper

18.11.2009

» http://www.ncbi.nlm.nih.gov/sites/

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

Blood. 2009 Aug 6;114(6):1166-73. Epub 2009 May 21
21.09.2009

» http://www.ncbi.nlm.nih.gov/sites/

Farewell celebration of Prof dr Georges Fillet. CHU Sar Tilman, Liège. Past, present and future in the treatment of acute myeloid leukemia. An EORTC perspective.

05.09.2009

» http://www.ncbi.nlm.nih.gov/sites/

Assistentenvereniging Klinische Biologie (FAKB), KULeuven, UZ Gasthuisberg. Klinische aspecten en huidige therapie voor acute myeloide leukemie.

27.06.2009

» http://www.ncbi.nlm.nih.gov/sites/

V European Haematology Association 2009, Berlijn. Efficacy and safety of romiplostim vs medical standard of care as chronic therapy for nonsplenectomized patients with immune thrombocytopenia.

04.06.2009

» http://www.ncbi.nlm.nih.gov/sites/

V European Haematology Association 2009, Berlijn. The use of iron chelation thearpy for transfusion dependent myelodysplastic syndrome patients: a cross sectional study in Belgium.

04.06.2009

» http://www.ncbi.nlm.nih.gov/sites/

Celgene 2nd MDS Colloquium, Barcelona, Palau de Congressos de Catalunya, Workshop on Clinical use of Vidaza in Myelodysplastic syndromes.

15.04.2009

» http://www.ncbi.nlm.nih.gov/sites/

Belgian Haematological Society, Oostende. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.

30.01.2009

» http://www.ncbi.nlm.nih.gov/sites/

24 th meeting of Belgian Haematological Society, Thermae Palace Oostende. Amgen Satellite Symposium. “Update on romiplostim trials in ITP”.

30.01.2009

» http://www.ncbi.nlm.nih.gov/sites/

Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.

Acta Clinica Belgica, 2009;64-5.
01.01.2009

» http://www.ncbi.nlm.nih.gov/sites/

Analysis of the progression of JAK2 V617F positive myeloproliferative neoplasms by single-nucleotide polymorphism array does not reveal a strong chromosomal instability.

Cancer Genet Cytogenet 2009 Jul 15;192(2):102-4
01.01.2009

» http://www.ncbi.nlm.nih.gov/sites/

The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation.

Submitted to Blood
01.01.2008

» http://www.ncbi.nlm.nih.gov/sites/

EVI1 overexpression in t(3,17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.

Submitted to Haematologica
01.01.2008

» http://www.ncbi.nlm.nih.gov/sites/

Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis and candida infections in Belgium.

Submitted to Acta Clinica Belgica
01.01.2008

» http://www.ncbi.nlm.nih.gov/sites/

Allogeneic Hematopoietic Stem cell Transplantation (HSCT) improves probability of survival in patients with high risk myelodysplastic syndromes: a prospective randomized comparison of allogeneic HSCT, autologous SCT or chemotherapy.

Submitted to New England Journal of Medicine
01.01.2008

» http://www.ncbi.nlm.nih.gov/sites/

Clinical challenges and images in GI. Fasciola hepatica infection and Von Hippel-Lindau disease type 1 with pancreatic and renal involvement.

Gastroenterology 2007;132:15-6, 467-8.
01/01/2007

» http://www.ncbi.nlm.nih.gov/pubmed/

Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient.

Transpl Infect Dis. 2007;9:126-31
01.01.2007

» http://www.ncbi.nlm.nih.gov/sites/

Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.

Cancer Genet Cytogenet. 2007;178:11-6
01.01.2007

» http://www.ncbi.nlm.nih.gov/sites/

High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600×109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.

Blood. 2007;109:1334-5
01.01.2007

» http://www.ncbi.nlm.nih.gov/sites/

Clinical challenges and images in GI. Fasciola hepatica infection and Von Hippel-Lindau disease type 1 with pancreatic and renal involvement.

Gastroenterology. 2007;132:15-6, 467-8
01.01.2007

» http://www.ncbi.nlm.nih.gov/sites/

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

Blood 2007;110:1456
01.01.2007

» http://www.ncbi.nlm.nih.gov/sites/

Results of Haploidentical Stem Cell Transplantation after a Conditioning Regimen without Total Body Irradiation in Elderly Patients with Advanced Myeloid and Lymphoid Malignancies.

Blood 2007;110: 3074
01.01.2007

» http://www.ncbi.nlm.nih.gov/sites/
Toon meer